⌛ Did you miss ProPicks’ 13% gains in May? Subscribe now & catch June’s top AI-picked stocks early.Unlock Stocks

Cathie Wood’s ARK ETFs buy Roku, Twist Bioscience stock

EditorFrank DeMatteo
Published 13/04/2024, 01:10

In the latest trading session, Cathie Wood's ARK ETFs exhibited a blend of strategic buys and sells, with Roku Inc (NASDAQ:ROKU) and Twist Bioscience Corp (NASDAQ:TWST) leading the purchases. On Friday, April 12, 2024, ARK's flagship funds engaged in several significant transactions, reflecting Wood's ongoing confidence in the biotech and tech sectors.

ARK's largest buy for the day was in Roku Inc (NASDAQ:ROKU), where the funds scooped up 66,301 shares across ARKK and ARKW, amounting to a substantial investment of $4,107,347. This move signals ARK's bullish stance on the streaming platform, which has been a recurring theme in the fund's recent activity.

Twist Bioscience Corp (NASDAQ:TWST), a synthetic biology company, also saw a major influx of capital from ARK with the purchase of 132,782 shares, valued at $4,339,315. The consistent accumulation of TWST shares underscores ARK's optimism about the company's growth prospects in the burgeoning field of genetic research.

In the biotech space, ARK continued to increase its positions, buying 56850 shares of Arcturus Therapeutics (NASDAQ:ARCT) Holdings Inc (NASDAQ:ARCT) for $1,849,899, and adding 371,597 shares of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) at a total value of $3,314,645. Both companies are working on innovative treatments that could potentially disrupt the healthcare market.

Telemedicine also remained in focus, with ARK purchasing 192,277 shares of Teladoc Health Inc (NYSE:NYSE:TDOC) across multiple funds, totaling an investment of $2,807,244. This acquisition aligns with ARK's thematic investment in digital health technologies, which Wood has frequently championed.

On the sell side, ARK offloaded shares in several companies, including a sale of 202,466 shares of Nu Holdings Ltd (NYSE:NU) for $2,338,482 and 2743 shares of Nvidia Corp (NASDAQ:NVDA) at a value of $2,485,596. These divestitures may reflect ARK's portfolio rebalancing or a strategic shift in response to market conditions.

Other notable trades included the sale of 8115 shares of Exact Sciences Corp (NASDAQ:EXAS) for $591,989 and 35727 shares of UiPath Inc (NYSE:NYSE:PATH) valued at $761,342, indicating a possible reallocation of resources within the healthcare and tech sectors.

ARK's daily trades reveal a strategic emphasis on genomic innovation and technology platforms, with a pattern of reinforcing positions in companies poised for long-term growth. Investors following ARK's movements may find these trends indicative of the fund's broader investment thesis.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.